Tony Berberabe, M.P.H.

Updated Analysis of Prostate Cancer Trials Continue to Demonstrate Benefit with Xtandi

March 24, 2015

Two studies investigating Xtandi in men with early-stage metastatic castration-resistant prostate cancer (mCRPC) further confirmed the overall survival (OS) and progression-free survival (PFS) benefit of the agent over placebo, according to two recent studies.

Oncology Society Endorses Guidelines for Prostate Cancer Survivor Care

February 16, 2015

ASCO has endorsed new prostate cancer survivorship care guidelines from the American Cancer Society that provide a structure to help prostate cancer patients with localized disease to receive high quality care from specialists and primary care physicians.